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After an acute stroke, systemic infection can complicate the recovery process and lead to a 
worse clinical outcome, including a higher risk of mortality. Post-stroke infection (PSI) is 
responsible for the majority of the mortality occurring between 1 week and 1 month after 
stroke, peaking towards the end of the second week. The effects of PSI on longer-term 
outcome and other aspects of recovery, such as cognition, mood and quality of life, are 
largely unknown. The cerebrovascular event itself may result in a systemic 
immunosuppressed state, hence lowering the threshold for subsequent systemic bacterial 
infections. Although there have been advances in the basic understanding of the 
pathophysiological mechanisms of PSI, clinical studies have not provided any clear 
guidelines on the best methods of managing or preventing PSI. This article provides a 
review of the current knowledge of the phenomenon of PSI and the possible future 
developments in the understanding and treatment of PSI.
Infection & risk of stroke
In the past decade, there has been an increasing
understanding in the complexity of the relation-
ship between chronic infection, inflammation,
and atherosclerotic diseases, including myocardial
infarction and stroke [1,2]. Many studies have
demonstrated that serum markers of Helicobacter
pylori,  Chlamydia pneumoniae,  Cytomegalovirus
and odontopathogens may predict the future risk
of cerebrovascular disease, even after adjusting for
traditional risk factors and socio–economic status
[3–5]. However, other studies have not found sig-
nificant associations [6]. The relationship between
chronic infection and cardiovascular and cere-
brovascular diseases remains controversial and any
causal links are far from being proven [7–9]. What
is more widely accepted is that markers of inflam-
mation, and in particular C-reactive protein, can
independently predict future cardiovascular and
cerebrovascular events [10–14].
Frequency of occurrence of 
post-stroke infections
After an acute stroke, the patient is at high risk
of developing many medical and neurological
complications, one of the most common being
post-stroke infection (PSI). These complications
can seriously prolong and challenge the recovery
process as well as increase the risk of mortality
and morbidity [15]. In a large, hospital-based
German Stroke Databank, the most common
serious medical complications in the first week
of hospitalization were recurrent stroke and
pneumonia  [16]. In a large UK-based study,
pneumonia and urinary tract infections (UTIs)
were the most frequently observed medical
complications [17]. 
In general, PSIs are found to occur in 25–65%
of patients admitted to hospital with acute stroke
[15,17–23]. In these studies, pneumonia occurs in
4–22% of all stroke patients, and UTIs occur in
3–44% [15,17–19,21,24–28].
There are many possible reasons for the wide
variations in frequencies reported by the observa-
tional studies. In particular, investigators have
used different methods of patient selection, diag-
nostic criteria for PSI and duration of observation
[29]. Nonseptic fever can sometimes be misinter-
preted as PSI (and treated with antibiotics) if
physical examination reveals confusing clinical
signs and if the necessary investigations are not
undertaken to confirm the presence of bacteria. 
PSI is associated with significant additional
hospital and community costs. The average extra
cost of hospitalization was estimated to be
US$ 14,000 higher for patients with post-stroke
pneumonia compared with those who did not
suffer pneumonia [30]. In this study, patients with
post-stroke pneumonia were also 70% more
likely to be discharged with requirements for
community care, and the cost of this is likely to
be very substantial.
Stroke as a risk factor for 
developing infection
Although infection is common after stroke, and
some studies have found an association between
stroke and hospital-acquired infections [31,32], 
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there is no clear evidence whether acute stroke
per se independently increases the risk of sys-
temic infections, or whether the risk is higher
purely as a result of the consequences of being
acutely unwell (e.g., immobility and poor
nutritional state) [33,34]. It is well known that
other nonstroke acute medical conditions can
also lead to hospital-acquired infections, and
s t u d i e s  h a v e  r e p o rt e d v e ry  wi de  v a r i a t i o n s  i n
the frequency of their occurrence, from very
low (2–10%) [32,35] to levels found amongst
stroke cohorts (∼20%) [36].
Whether transient ischemic attack (TIA)
increases the risk of PSI is much less clear. In one
large prospective study of patients admitted with
stroke or TIA, patients with stroke had an 18%
risk of developing PSIs within the first week,
whereas patients with TIA had a 15% risk of
developing PSI [29]. These numbers are, of
course, very small and cannot lead to definitive
conclusions, but if TIA could also increase the
risk of infections, then it is potentially a very
interesting finding. In particular, it leads to sev-
eral hypotheses: a) that an acute cerebrovascular
event (whatever the duration) could lead to
pathological processes (e.g., immunodeficiency)
that may predispose the patient to infections,
even though TIA is associated with a signifi-
cantly shorter duration of neurological deficit; b)
the harmful exposure to hospital environment is
a much more important contributor to the
development of PSI than the severity or duration
of neurological symptoms; and c) certain sub-
groups of patients with TIA may be more sus-
ceptible to PSI, for example those with
permanent neuronal damage (such as those
detectable on diffusion-weighted MRI).
Reasons for developing infection 
after stroke
After an acute stroke (especially with a more
severe stroke), the neurological and functional
deficits lead to a higher level of dependency,
which can potentially predispose a patient to
P S I .  I n  o n e  r e c e n t  s t u d y ,  d y s p h a g i a ,  u r i n a r y
incontinence (and urinary catheterization) and
reduced level of consciousness were found to be
predisposing factors for PSI [29]. Dysphagia is
known to increase the risk of aspiration pneumo-
nia, dehydration and malnutrition [37–39]. Previ-
ous studies have shown that approximately half
of all stroke patients with dysphagia will experi-
ence aspiration, and over a third of these patients
will develop aspiration pneumonia and approxi-
mately half will develop malnutrition [37]. A
reduced level of consciousness can further
increase the risk of aspiration by downregulating
the patient’s cough reflex, leading to poor clear-
ance of secretions [40]. Interventions such as
nasogastric feeding, which are traditionally
regarded as safe methods of providing nutrition
for patients at risk of aspiration, have been
shown to only provide limited protection against
aspiration pneumonia [41]. 
Urinary incontinence, which is very common
after acute stroke, can result in perineal macera-
tion and skin breakdown (and hence cellulitis)
[42]. Despite a clear causal link between urinary
catheterization and UTI [31], acute stroke
patients are still commonly managed using a uri-
nary catheter, especially during the early period
[43]. Urinary catheterization not only encourages
bacterial growth [44,45], but the formation of a
biofilm that forms on the inside of the indwell-
ing catheter also serves to protect the causative
bacteria from host defences and antibiotic ther-
apy, hence conveying a survival advantage to the
bacteria [31]. In 2007, Kwan et al. demonstrated
that urinary catheterization increased the odds of
developing a post-stroke UTI by three- to four-
fold, even after adjusting for case mix [29]. Inter-
estingly, this study also showed that urinary
catheterization increased the odds of developing
pneumonia after stroke by two- to threefold, but
the reasons for this were unclear [29]. Other
potential reasons why acute stroke patients can
be predisposed to PSI include malnutrition [46],
the use of peripheral or central venous catheters,
hyperglycemia and prolonged bed-rest. 
Other risk factors for developing 
post-stroke infection
Several studies have tried to identify other pre-
dictors for PSI [16,24,29,47–51]. In one recent large
prospective series, patients who experienced PSI
within the first week of admission were on aver-
age 5 years older, significantly more dependent
before admission, had more severe strokes (40 vs
20% suffering a total anterior circulation stroke),
and were more likely to have urinary catheters
inserted on admission [29]. Cerebral haemorrhage
does not appear to be a significant predictor of
PSI. Other studies have also confirmed the asso-
ciation between PSI and markers of stroke sever-
ity [24,51], as well as the arterial territory affected
by the stroke (e.g., middle cerebral artery terri-
tory  [49] and brainstem [50]). Speech difficulty,
level of disability on admission, and poor mental
test scores have been found to independently
predict the development of pneumonia after 
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stroke  [52]. High post-voiding residual bladder
volume, level of education and level of motor
function recovery have also been found to
predict the development of UTI after stroke [31]. 
Several laboratory parameters have been
found to be predictors of PSI. In one study,
patients with PSI had a significantly higher level
of serum urea (an indication of dehydration),
and a lower platelet count [29]. In another study,
lower level of serum albumin was also found to
independently predict post-stroke pneumonia
[53]. Neuroimaging parameters, such as infarct
size, can also be associated with PSI, as demon-
strated by one recent study [54]. Whether genetic
polymorphism/s in inflammatory or immune-
mediated genes are associated with susceptibility
to and outcome of PSI is still under debate [55,56].
Possible candidate genes include TNF-α and -β
genes,  IL-6,  IL-10,  CD-14 and the Toll-like
receptor (TLR)-4 genes [57].
Stroke-induced
immunodeficiency syndrome
Patients with acute stroke may also be at a higher
risk of PSI because of a reduced ability to fight
infections. Evidence from animal experiments
supports the existence of a ‘stroke-induced
immunodeficiency syndrome’ [58–60]. In one
experiment, focal ischemic stroke induced an
extensive apoptotic loss of lymphocytes and a
shift from T helper (Th) cells to Th2 cytokine
production, and these changes were associated
with spontaneous bacteremia and pneumonia
[60]. Prass et al. also found that stroke propagated
bacterial aspiration to the development of pneu-
monia (even with very small bacterial colonies),
and this propagation could be successfully
prevented by β-adrenoreceptor blockade [61].
The CNS can modulate the activity of the
immune system through complex neuro–humoral
pathways, including the hypothalamus–pitui-
tary–adrenal (HPA) axis, the vagus nerve and the
sympathetic nervous system [62,63]. In one study,
p a t i e n t s  w i t h  a c u t e  s t r o k e  w e r e  f o u n d  t o  h a v e
impaired cell-mediated immunity (e.g., reduced
number of T lymphocytes) but not humoral
immunity  [64]. However, this study was uncon-
trolled and did not collect data on infection.
Another study found that the immunosuppres-
sion after acute stroke may be endogenous. The
authors demonstrated that plasma IL-1-receptor
antagonist concentration is increased, and
cytokine induction was suppressed, during the
early recovery period after stroke [54]. On the other
hand, immunosuppression after stroke might also
have potentially beneficial effects, such as by sup-
pressing autoaggressive responses during lesion-
induced exposure of CNS-specific antigens to the
immune system [62]. Currently, there is insuffi-
cient knowledge about the frequency of stroke-
induced immunodeficiency syndrome in man, the
biological mechanisms that might underpin it and
how long the syndrome lasts for [65].
Post-stroke infection & recovery
Many studies have demonstrated that PSI may
lead to poor functional outcome [24,29,48–51], but
this finding is not universal across all studies, and
the relationship between PSI and functional out-
come remains unclear [20,66]. Owing to the com-
plexity of the pathophysiological process of acute
stroke, and the variation in the process of acute-
stroke care, it is possible that previous studies of
functional outcome have not completely
adjusted for case-mix and other crucial factors
that could have potentially affected the outcome.
This could have led to false-positive (or
-negative) correlations with functional outcome.
Although many studies have studied stroke-
associated infections (SAIs), some have not dis-
tinguished between pre- and post-stroke infec-
tions, which might have potentially important
differences in their prognosis. In particular, pre-
stroke systemic infections usually result in a sig-
nificant systemic inflammatory response (e.g.,
fever, tachycardia, hypotension and leucocyto-
sis), which is already present at the onset of
stroke (and remains for the first few hours or
days of recovery). This can have potentially dele-
terious effects on the ischemic cascade, hence
further impairing neuronal function and sur-
vival, leading to poorer functional outcome. In
contrast, PSIs that occur several days or weeks
after the initial event may not have the same
effect on neuronal function and survival because
the initial (and most damaging) pathophysiolog-
ical processes may already have stabilized. We are
currently testing these hypotheses through a
large-scale prospective study. 
Effects of post-stroke infection 
on outcome
There is accumulating evidence that PSI may be
associated with a poor short-term outcome,
including in-hospital death, functional recovery
and institutionalization on discharge; and these
associations are independent of stroke severity,
age and pre-stroke level of independence
[24,48–51]. However, not all studies have found
such an association [20,66]. PSI has been shown to 
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be one of the leading causes of death during the
early recovery period after stroke [67–69]. One
population-based study found that respiratory
infections accounted for 22% of deaths during
the first month, and for 26% of deaths during
the first year after ischemic stroke [70]. From the
German Stroke Register, pneumonia was the
complication with the highest attributable pro-
portion of death for the entire stroke population,
accounting for 31% of all stroke-related deaths
[16]. Kwan et al. found that patients who experi-
enced PSI had three-times the probability of
dying within the first 5 days compared with
those who did not experience PSI [29]. In this
study, the authors also showed that the associa-
tion with short-term outcome was independent
of case mix, stroke severity and adverse physio-
logical disturbances including fever, hypoxia and
hyperglycemia (which could also independently
affect outcome) [29].
The correlation with early functional outcome
has been less vigorously studied. In one prospec-
tive study, post-stroke pneumonia was signifi-
cantly associated with poor functional outcome
(Barthel index and Rankin score) and neurologi-
cal status (NIHSS) [24]. In Kwan et al., the
authors also found an association between PSI
and discharge destination, early post-stroke
seizures and occurrence of pressure sores [29]. In
this study, PSI was also found to increase the
overall length of stay in the acute hospital by
7 days. Again, the interpretation of these find-
ings can be complicated by the effects of the
many potential confounding factors, such as
stroke severity, case-mix and variations in process
of acute stroke care. Hence, it may be difficult to
draw definitive conclusion about the causality of
these complex relationships.
The effects of PSI on longer-term outcomes
are virtually unknown. In one study, post-stroke
pneumonia was found to increase the relative
risk of 1-month mortality threefold [51]. The
relationship between PSI and longer-term out-
comes, including motor and functional recovery,
cognition, mood and quality of life, are currently
being investigated in ongoing clinical studies.
Pathophysiological mechanism to 
explain influence on outcome
Post-stroke infection is responsible for the
majority of the deaths occurring between 1 week
and 1 month after stroke, peaking towards the
end of the second week. During this highly
unstable period of early stroke recovery, PSI may
lead to neurological deterioration by causing
homeostatic disturbances (e.g., hyperglycaemia,
fever, acidosis and excitotoxicity) [71–73], haemo-
static activation (e.g., excessive thrombin genera-
tion and fibrin turnover) [74,75] and an
overwhelming inflammatory response that can
lead to hypotension and shock [76]. In one study,
early neurological deterioration after the initial
stroke was associated with an acute-phase
response on admission, including higher leuko-
cyte count, higher body temperature and a
higher fibrinogen level [75].
PSI often leads to fever, and there is good evi-
dence that fever is an independent predictor for
higher mortality and morbidity after stroke [77].
The harmful effects of fever have been attributed
to increased metabolic demands, changes in per-
meability of the blood–brain barrier, acidosis and
an increased release of neurotransmitters [73,78].
Studies using animal models of focal and global
ischemia have demonstrated that cerebral hyper-
thermia (over 39° C) can lead to larger infarct vol-
ume and more severe histological outcome
[73,79–81]. However, in humans, the effects of PSI
on other important physiological parameters,
such as infarct volume, cardiovascular function,
homeostatic control and cerebral hemodynamics
remain unclear, but may individually affect
outcome via different pathways. 
Inflammatory response, infection 
& outcome
Markers of systemic inflammatory response are
commonly raised after acute stroke, especially
when PSI has occurred [82]. There is now good
consensus that markers of acute-phase response
such as highly sensitive (hs) C-reactive protein
(CRP) could independently predict unfavorable
outcome and stroke recurrence [83–85]. Further-
more, admission CRP also predicts mortality
among patients treated with thrombolysis, and
early recanalization does not ameliorate the neg-
ative prognostic impact of elevated CRP [86]. 
However, there is much controversy about
whether inflammation is beneficial or harmful
after ischemic stroke [87,88]. On the one hand, cer-
tain proinflammatory cytokines (e.g., IL-6 and
TNF-α) can enhance cell death, neurodegenera-
tion and increase the extent of ischemic injury [87].
Moreover, inflammation can influence coagula-
tion (i.e., prothrombotic) and endothelial dys-
function  [89], which may lead to further
microvascular compromise, as well as increasing
metabolic demand by causing hyperthermia [87].
CRP may also induce inflammatory damage after
stroke by activating matrix metalloproteinase [90] 
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as well as monocyte adhesion [91]. The integrity of
the blood–brain barrier can also be disrupted after
acute stroke, and the systemic immune system
may encounter novel CNS antigens that can lead
to CNS antigen-specific autoimmune response. It
has been proposed that systemic infection after
stroke may promote a deleterious CNS autoim-
mune response that could result in further neuro-
nal damage and worse outcome [92]. However,
recent evidence suggests that acute systemic
inflammation may switch the phenotype of brain
macrophages and microglia responding to neuro-
degeneration and promote an aggressive
proinflammatory phenotype [93,94].
On the other hand, certain anti-inflammatory
cytokines (e.g., IL-10) and even some proinflam-
matory cytokines (e.g., TNF-α) have been shown
to possess neuroprotective properties. Macro-
phages may also have neuroprotective and growth-
promoting potentials in animal studies [88]. Clini-
cal studies of anti-inflammatory agents (e.g., anti-
ICAM-1 antibody and IL-1-receptor antagonist)
have not demonstrated any significant benefit, but
some clinical trials are still ongoing [95,96]. 
There are only a limited number of studies on
the cytokine response in humans with PSI [54,82].
One small study found that patients with PSI had
higher levels of certain types of proinflammatory
cytokines, especially IL-6 and 55 kD soluble
TNF receptors (sTNFR-p55), but not others
such as IL-1β, TNF-α or sTNFR-p75 [97]. The
authors suggested that local brain synthesis and
systemic release of proinflammatory cytokines
might precede the conventional systemic response
to infection, such as fever, hepatic synthesis of
acute phase proteins and leucocytosis. 
Diagnosing post-stroke infections
Early detection and treatment of PSIs has been
highlighted as one of the possible reasons why
organized stroke unit care leads to better survival
and outcome [98,99], and certainly it has been
incorporated as one of the major elements of
acute-stroke management [100]. The most impor-
tant aspect of managing PSIs is a low threshold for
suspecting a diagnosis. However, in clinical prac-
tice it can be extremely difficult to be certain of
the diagnosis, mainly because the clinical symp-
toms and signs can be difficult to establish, and
what may be regarded as abnormal clinical find-
ings of an infection may actually be common
sequelae after stroke (unrelated to an infection).
For instance, symptoms of pneumonia usually
include productive cough and fever. However,
after stroke, the cough reflex might be suppressed,
upper airway transmitted noises can frequently be
heard because of poor swallow and fever can often
be observed in the absence of infection. In the
Copenhagen Stroke Study, 25% of acute stroke
patients experienced fever, and of these only 16%
had proven concurrent infection and 50% had a
leucocytosis [101]. Moreover, clinical signs of pneu-
monia, such as inspiratory crackles and reduced
breath sounds, are very nonspecific and can often
be found in patients without pneumonia. In
patients with communication and cognitive disa-
bility acquired through acute stroke, in particular,
it may be difficult to establish a clear history (e.g.,
whether aspiration has occurred) and to carry out
a full clinical examination (e.g., not understand-
ing examiner’s command), and hence to deter-
mine whether a PSI is present. For these reasons,
diagnoses of PSI may be falsely made and treat-
ment administered unnecessarily, or rehabilitative
therapy unnecessarily interrupted, which can
potentially lead to a longer hospital stay.
It is also unclear whether the accuracy of diag-
nosis of PSI is substantially increased with the
aid of standard investigations. For example, the
chest radiograph may show abnormal shadowing
for reasons other than an infection, such as pul-
monary edema and fibrosis. A negative chest
radiograph does not exclude a diagnosis of pneu-
monia or lower respiratory tract infection. Uri-
nary microscopy and culture may also be
inaccurate when the patient has been catheter-
ized, which is common practice in many acute
stroke units [43]. Overall, the sensitivity and spe-
cificity of diagnosing PSI in the acute recovery
period are currently unknown. New markers of
bacterial sepsis (e.g., procalcitonin), some of
which are available as bedside tests, may be more
accurate in establishing a firm diagnosis of PSI
[102–104]. In patients with head injury, a new
qualitative IL-6 bedside test has been developed,
and this test is claimed to be useful in predicting
the risk of developing pneumonia [105].
Management of post-stroke infections
The mainstay of treatment of PSIs is antibiotic
therapy, either enterally (orally or via a nasogastric
tube) or intravenously. Evidence from animal
studies suggests that early or prophylactic antibi-
otic therapy could prevent the occurrence of PSIs
and fever, and significantly reduce the risk of
death or poor neurological outcome [106]. Sadly,
this benefit has not been translated to human
subjects. One clinical trial failed to demonstrate
any benefit in administrating prophylactic
antibiotic therapy after acute stroke [18].  
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Interestingly, some pharmaceutical agents
have been noted in clinical trials to reduce the
risk of post-stroke pneumonia, including cilosta-
zol (a phosphodiesterase inhibitor) [107], perindo-
pril (an angiotensin-converting enzyme
inhibitor) [108–112] and amantadine (an antiviral
agent that also increases dopamine release from
dopaminergic nerve terminals) [113]. Large-scale
randomized trials involving these agents are not
yet available. Certain antibiotic agents have also
been found to possess neuroprotective properties
in animal models of stroke. For instance, minoc-
ycline may be neuroprotective through its bene-
ficial effects on inflammation, microglial
activation, matrix metalloproteinases, nitric
oxide production, oxidative stress and apoptotic
cell death [114–116].  β-lactam antibiotics might
also be neuroprotective through preventing
glutamate-induced neurotoxicity [117], although
the mechanisms of action of β-lactam in this
regard remain unclear. Owing to the good safety
data and extensive experience with these agents,
these antibiotics may have a potential to become
neuroprotective treatments for acute stroke [118].
Many aspects of patient care that may poten-
tially be important in preventing PSIs have not
undergone formal evaluation through rand-
omized controlled trials. For example, alternative
methods of feeding (e.g., via nasogastric tube)
have traditionally been regarded as safe and effec-
tive in avoiding aspiration of gastric content.
However, this concept has been seriously chal-
lenged when one prospective study found that
pneumonia occurred in 44% of tube-fed stroke
patients [41], and in another study, 64% of bedrid-
den tube-fed stroke patients suffered pneumonia
[119]. Tube feeding was even found to be the
strongest predisposing factor for PSI in another
study  [20]. The influence of positioning of the
acute-stroke patient is also unclear. Although
positioning has been found to influence arterial
oxygen saturation and heart rate after stroke [120],
the relationship between positioning and occur-
rence (or prevention) of PSI has not been investi-
gated. Similarly, it remains unproven whether
post-stroke pneumonia can be prevented by deep
breathing exercises, speech and language therapy
(from specialists who also provide swallowing
assessment), or by the use of fluid thickener (to
prevent aspiration). Avoidance of urinary cathe-
terization in the acute recovery period is one obvi-
ous method of preventing UTIs [31], but many
other strategies are also potentially beneficial. For
example, the use of antimicrobial-impregnated
urinary catheters, or the administration of an anti-
biotic agent at the time of catheterization, may
prevent subsequent infection [121,122]. However,
these hypotheses have not been formally tested in
patients with acute stroke.
Conclusion
After an acute stroke, PSI can complicate the
recovery process and lead to a worse clinical out-
come, including a higher risk of mortality. The
effects of PSI on longer-term outcome and other
aspects of recovery, such as cognition, mood and
quality of life, are largely unknown. The cere-
brovascular event itself may result in a systemic
immunosuppressed state, hence lowering the
threshold for subsequent systemic bacterial
infections. Although there have been advances in
the basic understanding of the pathophysiologi-
cal mechanisms of PSI, clinical studies have not
provided any clear guideline on the best methods
of managing or preventing PSI. 
Future perspective
At the present time, the optimal management
strategy for SAI in stroke patients is unclear.
Future studies should adopt a combined transla-
tional approach to study the clinical phenomenol-
ogy as well as the underlying mechanisms. In
particular, future preclinical and clinical studies
will better define the frequency and effects of
stroke-induced immunosuppression, and how
this relates to the neural and peripheral inflamma-
tory response after stroke, and how this can in
turn lead to the occurrence and long-term conse-
quences of SAI. With better data from large and
well designed longitudinal studies, it will be possi-
ble to seek out those patients who have just
started developing an SAI (but before clinical
manifestation), in whom immediate antibiotic
therapy may help to avert a more severe SAI.
Moreover, it will be possible to predict who will
develop SAI in the subsequent few days, and who
will have a poor outcome as a result of the SAI.
For these patients, it may be possible to manage
them differently to prevent the occurrence of or a
bad outcome after an SAI.
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Executive summary
￿ After an acute stroke, systemic infection can complicate the recovery process and lead to a worse 
clinical outcome, including a higher risk of mortality.
￿ The effects of post-stroke infection (PSI) on longer-term outcome and other aspects of recovery, such 
as cognition, mood and quality of life, are largely unknown.
￿ The cerebrovascular event itself may result in a systemic immunosuppressed state, hence lowering the 
threshold for subsequent systemic bacterial infections.
￿ Although there have been advances in the basic understanding of the pathophysiological mechanisms 
of PSI, clinical studies have not provided any clear guideline on the best methods of managing or 
preventing PSI.
Bibliography
Papers of special note have been highlighted as 
either of interest (￿) or of considerable interest (￿￿) 
to readers.
1. Stoll G, Bendszus M: Inflammation and 
atherosclerosis: novel insights into plaque 
formation and destabilization. Stroke 37(7), 
1923–1932 (2006).
2. Emsley HC, Tyrrell PJ: Inflammation
and infection in clinical stroke. J. Cereb. 
Blood Flow Metab. 22(12), 1399–1419 
(2002).
3. Elkind MS, V, Lin I-F, Grayston JT, 
Sacco RL: Chlamydia pneumoniae and the 
risk of first ischemic stroke: the northern 
Manhattan stroke study. Stroke 31(7), 
1521–1525 (2000).
4. Preusch MR, Grau AJ, Buggle F et al.: 
Association between cerebral ischemia and 
cytotoxin-associated gene-A-bearing strains 
of Helicobacter pylori. Stroke 35(8), 
1800–1804 (2004).
5. Cremonini F, Gabrielli M, Gasbarrini G, 
Pola P, Gasbarrini A: The relationship 
between chronic H. pylori infection, 
CagA seropositivity and stroke: 
meta-analysis. Atherosclerosis 173(2), 
253–259 (2004).
6. Epstein SE, Zhu J: Lack of association of 
infectious agents with risk of future 
myocardial infarction and stroke: definitive 
evidence disproving the infection/coronary 
artery disease hypothesis? Circulation 
100(13), 1366–1368 (1999).
7. Lindsberg PJ, Grau AJ: Inflammation and 
infections as risk factors for ischemic stroke. 
Stroke 34(10), 2518–2532 (2003).
8. Heuschmann PU, Neureiter D, Gesslein M 
et al.: Association between infection with 
Helicobacter pylori and Chlamydia 
pneumoniae and risk of ischemic stroke 
subtypes: results from a population-based 
case-control study. Stroke 32(10), 
2253–2258 (2001).
9. Haider AW, Wilson PW, Larson MG et al.: 
The association of seropositivity to 
Helicobacter pylori, Chlamydia pneumoniae, 
and cytomegalovirus with risk of 
cardiovascular disease: a prospective study. 
J. Am. Coll. Cardiol. 40(8), 1408–1413 
(2002).
10. Wakugawa Y, Kiyohara Y, Tanizaki Y et al.: 
C-reactive protein and risk of first-ever 
ischemic and hemorrhagic stroke in a 
general Japanese population: the Hisayama 
Study. Stroke 37(1), 27–32 (2006).
11. Rost NS, Wolf PA, Kase CS et al.: Plasma 
concentration of C-reactive protein and risk 
of ischemic stroke and transient ischemic 
attack: the Framingham study. Stroke 
32(11), 2575–2579 (2001).
12. Cao JJ, Thach C, Manolio TA et al.: 
C-reactive protein, carotid intima-media 
thickness, and incidence of ischemic 
stroke in the elderly: the cardiovascular 
health study. Circulation 108(2), 166–170 
(2003).
13. Wang Q, Hunt SC, Xu Q et al.: Association 
study of CRP gene polymorphisms with 
serum CRP level and cardiovascular risk in 
the NHLBI Family Heart Study. Am. 
J. Physiol. Heart Circ. Physiol. 291(6), 
H2752–H2757 (2006).
14. Di Napoli M, Papa F, Bocola V: C-reactive 
protein in ischemic stroke: an independent 
prognostic factor. Stroke 32(4), 917–924 
(2001).
15. Johnston KC, Li JY, Lyden PD et al.: 
Medical and neurological complications of 
ischemic stroke: experience from the 
RANTTAS trial. Stroke 29(2), 447–453 
(1998).
16. Heuschmann PU, Kolominsky-Rabas PL, 
Misselwitz B et al.: Predictors of in-hospital 
mortality and attributable risks of death 
after ischemic stroke: the German Stroke 
Registers Study Group. Arch. Intern. Med. 
164(16), 1761–1768 (2004).
17. Langhorne P, Stott DJ, Robertson L et al.: 
Medical complications after stroke: 
a multicenter study. Stroke 31(6), 
1223–1229 (2000).
18. Chamorro A, Horcajada JP, Obach V et al.: 
The early systemic prophylaxis of infection 
after stroke study: a randomized clinical 
trial. Stroke 36(7), 1495–1500 (2005).
•￿ Important randomized controlled trial.
19. Dromerick A, Reding MJ: Medical and 
neurological complications during inpatient 
stroke rehabilitation. Stroke 25, 358–361 
(1994).
20. Vargas M, Horcajada JP, Obach V et al.: 
Clinical consequences of infection in 
patients with acute stroke: is it prime time 
for further antibiotic trials? Stroke 37(2), 
461–465 (2006).
21. Davenport RJ, Dennis M, Wellwood I, 
Warlow C: Complications after acute stroke. 
Stroke 27, 415–420 (1996).
22. Georgilis K, Plomaritoglou A, Dafni U, 
Bassiakos Y, Vemmos K: Aetiology of fever 
in patients with acute stroke. J. Intern. Med. 
246(2), 203–209 (1999).
23. Weimar C, Roth MP, Zillessen G et al.: 
Complications following acute ischemic 
stroke. Eur. Neurol. 48(3), 133–140 (2002).
24. Aslanyan S, Weir CJ, Diener HC, Kaste M, 
Lees KR: Pneumonia and urinary tract 
infection after acute ischaemic stroke: 
a tertiary analysis of the GAIN International 
trial. Eur. J. Neurol. 11(1), 49–53 (2004).
25. Grau AJ, Buggle F, Schnitzler P et al.: 
Fever and infection early after ischemic 
stroke. J. Neurol. Sci. 171(2), 115–120 
(1999).
26. Kalra L, Yu G, Wilson K, Roots P: Medical 
complications during stroke rehabilitation. 
Stroke 26(6), 990–994 (1995).
27. Roth EJ, Lovell L, Harvey RL et al.: 
Incidence of and risk factors for medical 
complications during stroke rehabilitation. 
Stroke 32(2), 523–529 (2001). 
 
 
 
 
 
 
Author Proof 
REVIEW – Kwan, Jenkinson, Vassallo, Englyst & Perry 
8 Aging Health (2008)  4(1) future science group future science group
28. Dromerick AW, Edwards DF: Relation 
of postvoid residual to urinary tract 
infection during stroke rehabilitation. Arch. 
Phys. Med. Rehabil. 84(9), 1369–1372 
(2003).
29. Kwan J, Hand P: Infection after acute stroke 
is associated with poor short-term outcome. 
Acta Neurol. Scand. 115(5), 331–338 
(2007). 
￿ Large-scale prospective study.
30. Katzan IL, Dawson NV, Thomas CL, 
Votruba ME, Cebul RD: The cost of 
pneumonia after acute stroke. Neurology 
68(22), 1938–1943 (2007).
31. Ersoz M, Ulusoy H, Oktar MA, Akyuz M: 
Urinary tract infection and bacteriurua in 
stroke patients: frequencies, pathogen 
microorganisms, and risk factors. 
A m .J .P h y s .  M e d .  R e h a b i l .  86(9), 734–741 
(2007).
32. Graves N, Nicholls TM, Wong CG, 
Morris AJ: The prevalence and estimates of 
the cumulative incidence of hospital-
acquired infections among patients admitted 
to Auckland District Health Board 
Hospitals in New Zealand. Infect. Control 
Hosp. Epidemiol. 24(1), 56–61 (2003).
33. Livingston DH, Appel SH, Wellhausen SR, 
Sonnenfeld G, Polk HC Jr: Depressed 
interferon γ production and monocyte 
HLA-DR expression after severe injury. 
Arch. Surg. 123(11), 1309–1312 (1988).
34. Woiciechowsky C, Schoning B, 
Daberkow N et al.: Brain-IL-1β induces 
local inflammation but systemic anti-
inflammatory response through stimulation 
of both hypothalamic–pituitary–adrenal axis 
and sympathetic nervous system. Brain Res. 
816(2), 563–571 (1999).
35. Nguyen-Van-Tam SE, Nguyen-Van-Tam JS, 
Myint S, Pearson JC: Risk factors for 
hospital-acquired urinary tract infection in a 
large English teaching hospital: a case-
control study. Infection 27(3), 192–197 
(1999).
36. Hussain M, Oppenheim BA, O’Neill P 
et al.: Prospective survey of the incidence, 
risk factors and outcome of hospital-
acquired infections in the elderly. J. Hosp. 
Infect. 32(2), 117–126 (1996).
37. Doggett DL, Tappe KA, Mitchell MD 
et al.: Prevention of pneumonia in elderly 
stroke patients by systematic diagnosis and 
treatment of dysphagia: an evidence-based 
comprehensive analysis of the literature. 
Dysphagia 16(4), 279–295 (2001).
38. Martino R, Foley N, Bhogal S et al.: 
Dysphagia after stroke: incidence, diagnosis, 
and pulmonary complications. Stroke 
36(12), 2756–2763 (2005).
39. Marik PE: Aspiration pneumonitis and 
aspiration pneumonia. N. Engl. J. Med. 
344(9), 665–671 (2001).
40. Widdicombe J, Singh V: Physiological and 
pathophysiological down-regulation of 
cough. Respir. Physiol. Neurobiol. 150(2–3), 
105–117 (2006).
41. Dziewas R, Ritter M, Schilling M et al.: 
Pneumonia in acute stroke patients fed by 
nasogastric tube. J. Neurol. Neurosurg. 
Psychiatry 75(6), 852–856 (2004).
42. Werner GT, Gadomski M, Scheinert B: The 
significance of urinary tract infections in 
patients with cerebrovascular diseases during 
clinical rehabilitation. Rehabilitation 
(Stuttg.) 37(2), 64–67 (1998).
43. Roth EJ, Lovell L, Harvey RL, Bode RK, 
Heinemann AW: Stroke rehabilitation: 
indwelling urinary catheters, enteral feeding 
tubes, and tracheostomies are associated 
with resource use and functional outcomes. 
Stroke 33(7), 1845–1850 (2002).
44. Kwan J, Hand P, Sandercock PA, 
Dennis MS: What are the consequences of 
urinary catheterisation in patients with acute 
stroke? Cerebrovasc. Dis. 16(Suppl. 4), 26 
(2003). 
45. Johnson JR, Kuskowski MA, Wilt TJ: 
Systematic review: antimicrobial urinary 
catheters to prevent catheter-associated 
urinary tract infection in hospitalized 
patients. Ann. Intern. Med. 144(2), 116–126 
(2006).
46. FOOD Trial Collaboration: Poor 
nutritional status on admission predicts 
poor outcomes after stroke: observational 
data from the FOOD trial. Stroke 34(6), 
1450–1456 (2003).
47. Weimar C, Ziegler A, Konig IR, 
Diener HC: Predicting functional outcome 
and survival after acute ischemic stroke. 
J. Neurol. 249(7), 888–895 (2002).
48. Hilker R, Poetter C, Findeisen N et al.: 
Nosocomial pneumonia after acute stroke: 
implications for neurological intensive care 
medicine. Stroke 34(4), 975–981 (2003).
49. Hamidon BB, Raymond AA, Norlinah MI, 
Jefferelli SB: The predictors of early 
infection after an acute ischaemic stroke. 
Singapore Med. J. 44(7), 344–346 (2003).
50. Upadya A, Thorevska N, Sena KN, 
Manthous C, moateng-Adjepong Y: 
Predictors and consequences of pneumonia 
in critically ill patients with stroke. J. Crit. 
Care 19(1), 16–22 (2004).
51. Katzan IL, Cebul RD, Husak SH, 
Dawson NV, Baker DW: The effect of 
pneumonia on mortality among patients 
hospitalized for acute stroke. Neurology 
60(4), 620–625 (2003).
52. Sellars C, Bowie L, Bagg J et al.: Risk factors 
for chest infection in acute stroke: 
ap r o s p e c t i v e  c o h o r t  s t u d y .  Stroke 38(8), 
2284–2291 (2007).
53. Dziedzic T, Slowik A, Pera J, Szczudlik A: 
β-blockers reduce the risk of early death in 
ischemic stroke. J. Neurol. Sci. 252(1), 
53–56 (2007).
54. Smith CJ, Emsley HC, Vail A et al.: 
Variability of the systemic acute phase 
response after ischemic stroke. J. Neurol. Sci. 
251(1–2), 77–81 (2006).
55. Texereau J, Pene F, Chiche JD, Rousseau C, 
Mira JP: Importance of hemostatic gene 
polymorphisms for susceptibility to and 
outcome of severe sepsis. Crit. Care Med. 
32(Suppl. 5), S313–S319 (2004).
56. Schulte-Herbruggen O, Klehmet J, 
Quarcoo D, Meisel C, Meisel A: Mouse 
strains differ in their susceptibility to 
poststroke infections. 
Neuroimmunomodulation 13(1), 13–18 
(2006).
57. Holmes CL, Russell JA, Walley KR: Genetic 
polymorphisms in sepsis and septic shock: 
role in prognosis and potential for therapy. 
Chest 124(3), 1103–1115 (2003).
58. Meisel C, Schwab JM, Prass K, Meisel A, 
Dirnagl U: Central nervous system injury-
induced immune deficiency syndrome. Nat. 
Rev. Neurosci. 6(10), 775–786 (2005).
59. Woiciechowsky C, Schoning B, 
Lanksch WR, Volk HD, Docke WD: 
Mechanisms of brain-mediated systemic 
anti-inflammatory syndrome causing 
immunodepression. J. Mol. Med. 77(11), 
769–780 (1999).
60. Prass K, Meisel C, Hoflich C et al.: 
Stroke-induced immunodeficiency 
promotes spontaneous bacterial infections 
and is mediated by sympathetic activation 
reversal by poststroke T helper cell type 1-
like immunostimulation. J. Exp. Med. 
198(5), 725–736 (2003).
￿￿ Important preclinical study.
61. Prass K, Braun JS, Dirnagl U, Meisel C, 
Meisel A: Stroke propagates bacterial 
aspiration to pneumonia in a model of 
cerebral ischemia. Stroke 37(10), 
2607–2612 (2006).
62. Dirnagl U, Klehmet J, Braun JS et al.: 
Stroke-induced immunodepression: 
experimental evidence and clinical relevance. 
Stroke 38(Suppl. 2), 770–773 (2007).
￿ Important review on 
post-stroke immunodepression.
63. Chamorro A, Urra X, Planas AM: Infection 
after acute ischemic stroke: a manifestation 
of brain-induced immunodepression. Stroke 
38(3), 1097–1103 (2007). 
 
 
 
 
 
 
Author Proof 
Systemic infections after acute stroke – REVIEW
9 future science group future science group www.futuremedicine.com
64. Czlonkowska A, Korlak J: The immune 
response during aging. J. Gerontol. 34(1), 
9–14 (1979).
65. Haeusler KG, Schmidt WU, Fohring F 
et al.: Cellular immunodepression preceding 
infectious complications after acute ischemic 
stroke in humans. Cerebrovasc. Dis. 25(1–2), 
50–58 (2007).
66. Kammersgaard LP, Jorgensen HS, Reith J 
et al.: Early infection and prognosis after 
acute stroke: the Copenhagen Stroke Study. 
J. Cereb. Blood Flow Metab. 10(5), 217–221 
(2001). 
67. Henon H, Godefroy O, Leys D et al.: Early 
predictors of death and disability after acute 
cerebral ischemic event. Stroke 26(3), 
392–398 (1995).
68. Viitanen M, Winblad B, Asplund K: 
Autopsy-verified causes of death after stroke. 
Acta Med. Scand. 222(5), 401–408 (1987).
69. Daud-Gallotti R, Dutilh Novaes HM, 
Lorenzi MC et al.: Adverse events and death 
in stroke patients admitted to the emergency 
department of a tertiary university hospital. 
Eur. J. Emerg. Med. 12(2), 63–71 (2005).
70. Vernino S, Brown RD Jr, Sejvar JJ et al.: 
Cause-specific mortality after first cerebral 
infarction: a population-based study. Stroke 
34(8), 1828–1832 (2003).
71. Castillo J, Davalos A, Noya M: Progression 
of ischaemic stroke and excitotoxic 
aminoacids. Lancet 349(9045), 79–83 
(1997).
72. Greenberg JH: Glucose and oxygen 
metabolism in ischaemia. In: Cerebrovascular 
Disease. Pathophysiology, Diagnosis, and 
Management. Ginsberg MD, Bogousslavsky 
J (Eds). Malden Blackwell Science, MA, 
USA (1998).
73. Busto R, Ginsberg MD: The influence of 
altered brain temperature in cerebral 
ischaemia. In: Cerebrovascular Disease. 
Pathophysiology, Diagnosis, and Management. 
Ginsberg MD, Bogousslavsky J (Eds). 
Malden Blackwell Science, MA, USA 
(1998).
74. Barber M, Langhorne P, Rumley A, 
Lowe GD, Stott DJ: Hemostatic function 
and progressing ischemic stroke: D-dimer 
predicts early clinical progression. Stroke 
35(6), 1421–1425 (2004).
75. Audebert HJ, Pellkofer TS, Wimmer ML, 
Haberl RL: Progression in lacunar stroke is 
related to elevated acute phase parameters. 
Eur. Neurol. 51(3), 125–131 (2004).
76. Ashare A, Powers LS, Butler NS et al.: 
Anti-inflammatory response is associated 
with mortality and severity of infection in 
sepsis. Am. J. Physiol. Lung Cell Mol. Physiol. 
288(4), L633–L640 (2005).
77. Hajat C, Hajat S, Sharma P: Effects of 
poststroke pyrexia on stroke outcome: a 
meta-analysis of studies in patients. Stroke 
31(2), 410–414 (2000).
78. Dippel DWJ, van Breda EJ, 
van Gemert HMA et al.: Effect of 
paracetamol (acetaminophen) on body 
temperature in acute ischemic stroke: 
a double-blind, randomized Phase II clinical 
trial. Stroke 32(7), 1607–1612 (2001).
79. Reglodi D, Somogyvari-Vigh A, 
Maderdrut JL, Vigh S, Arimura A: 
Postischemic spontaneous hyperthermia and 
its effects in middle cerebral artery occlusion 
in the rat. Exp. Neurol. 163(2), 399–407 
(2000).
80. Coimbra C, Drake M, Boris-Moller F, 
Wieloch T: Long-lasting neuroprotective 
effect of postischemic hypothermia and 
treatment with an anti-
inflammatory/antipyretic drug. Evidence 
for chronic encephalopathic processes 
following ischemia. Stroke 27(9), 
1578–1585 (1996).
81. Schmid-Elsaesser R, Hungerhuber E, 
Zausinger S, Baethmann A, Reulen HJ: 
Combination drug therapy and mild 
hypothermia: a promising treatment strategy 
for reversible, focal cerebral ischemia. Stroke 
30(9), 1891–1899 (1999).
82. Emsley HC, Smith CJ, Gavin CM et al.: An 
early and sustained peripheral inflammatory 
response in acute ischaemic stroke: 
relationships with infection and 
atherosclerosis. J. Neuroimmunol. 139(1–2), 
93–101 (2003).
￿ Useful study on inflammation and 
infection after stroke.
83. Arenillas JF, varez-Sabin J, Molina CA et al.: 
C-reactive protein predicts further ischemic 
events in first-ever transient ischemic attack 
or stroke patients with intracranial large-
artery occlusive disease. Stroke 34(10), 
2463–2468 (2003).
84. Di Napoli M, Papa F, Bocola V: C-reactive 
protein in ischemic stroke: an independent 
prognostic factor. Stroke 32(4), 917–924 
(2001).
85. Muir KW, Weir CJ, Alwan W, Squire IB, 
Lees KR: C-reactive protein and outcome 
after ischemic stroke. Stroke 30(5), 981–985 
(1999).
86. Montaner J, Fernandez-Cadenas I, 
Molina CA et al.: Poststroke C-reactive 
protein is a powerful prognostic tool among 
candidates for thrombolysis. Stroke 37(5), 
1205–1210 (2006).
87. del Zoppo GJ, Becker KJ, Hallenbeck JM: 
Inflammation after stroke: is it harmful? 
Arch. Neurol.58(4), 669–672 (2001).
88. Feuerstein GZ, Wang X: Inflammation and 
stroke: benefits without harm? Arch. 
Neurol.58(4), 672–674 (2001).
89. Englyst N, Kwan J, Horsfield G, Bryant T, 
Gawne-Cain M, Byrne C: Infection and 
IL-6 are independent risk factors for a poor 
functional outcome from ischaemic stroke. 
Cerebrovasc. Dis. 23(Suppl. 2), 64 (2007). 
90. Montero I, Orbe J, Varo N et al.: C-reactive 
protein induces matrix metalloproteinase-1 
and -10 in human endothelial cells: 
implications for clinical and subclinical 
atherosclerosis. J. Am. Coll. Cardiol. 47(7), 
1369–1378 (2006).
91. Woollard KJ, Phillips DC, Griffiths HR: 
Direct modulatory effect of C-reactive 
protein on primary human monocyte 
adhesion to human endothelial cells. 
Clin. Exp. Immunol. 130(2), 256–262 
(2002).
92. Gee JM, Kalil A, Shea C, Becker KJ: 
Lymphocytes: potential mediators of 
postischemic injury and neuroprotection. 
Stroke 38(Suppl. 2), 783–788 (2007).
93. Cunningham C, Wilcockson DC, 
Campion S, Lunnon K, Perry VH: Central 
and systemic endotoxin challenges 
exacerbate the local inflammatory response 
and increase neuronal death during chronic 
neurodegeneration. J. Neurosci. 25(40), 
9275–9284 (2005).
94. Perry VH: Stress primes microglia to the 
presence of systemic inflammation: 
implications for environmental influences on 
the brain. Brain Behav. Immun. 21(1), 45–46 
(2007).
95. Emsley HC, Smith CJ, Georgiou RF et al.: A 
randomised Phase II study of 
interleukin-1 receptor antagonist in acute 
stroke patients. J. Neurol. Neurosurg. Psychiatry 
76(10), 1366–1372 (2005).
96. Enlimomab Acute Stroke Trial Investigators: 
Use of anti-ICAM-1 therapy in ischemic 
stroke: results of the Enlimomab Acute 
Stroke Trial. Neurology 57(8), 1428–1434 
(2001).
97. Fassbender K, Dempfle CE, Mielke O et al.: 
Proinflammatory cytokines: indicators of 
infection in high-risk patients. J. Lab. Clin. 
Med. 130(5), 535–539 (1997).
98. Govan L, Langhorne P, Weir CJ: Does the 
prevention of complications explain the 
survival benefit of organized inpatient (stroke 
unit) care?: further analysis of a systematic 
review. Stroke 38(9), 2536–2540 (2007).
99. Evans A, Perez I, Harraf F et al.: 
Can differences in management processes 
explain different outcomes between stroke 
unit and stroke-team care? Lancet 
358(9293), 1586–1592 (2002). 
 
 
 
 
 
 
Author Proof 
REVIEW – Kwan, Jenkinson, Vassallo, Englyst & Perry 
10 Aging Health (2008)  4(1) future science group future science group
100. Hack W, Kaste M, Bogousslavsky J et al.: 
European Stroke Initiative 
Recommendations for Stroke Management 
– update 2003. Cerebrovasc. Dis. 16(4), 
311–337 (2003).
101. Reith J, Jorgensen HS, Pedersen PM et al.: 
Body temperature in acute stroke: relation 
to stroke severity, infarct size, mortality, and 
outcome. Lancet 347(8999), 422–425 
(1996).
102. Oconnor E, Venkatesh B, Mashongonyika C 
et al.: Serum procalcitonin and C-reactive 
protein as markers of sepsis and outcome in 
patients with neurotrauma and subarachnoid 
haemorrhage. Anaesth. Intensive Care 32(4), 
465–470 (2004).
103. Gattas DJ, Cook DJ: Procalcitonin as a 
diagnostic test for sepsis: health technology 
assessment in the ICU. J. Crit. Care 18(1), 
52–58 (2003).
104. Miyakis S, Georgakopoulos P, Kiagia M et al.: 
Serial serum procalcitonin changes in the 
prognosis of acute stroke. Clin. Chim. Acta 
350(1–2), 237–239 (2004).
105. Schlosser HG, Volk HD, Splettstosser G, 
Brock M, Woiciechowsky C: A new 
qualitative interleukin-6 bedside test can 
predict pneumonia in patients with severe 
head injury – comparison to the standard 
Immulite test and a semiquantitative 
bedside test. J. Neurosurg. Anesthesiol. 19(1), 
5–9 (2007).
106. Meisel C, Prass K, Braun J et al.: Preventive 
antibacterial treatment improves the general 
medical and neurological outcome in a 
mouse model of stroke. Stroke 35(1), 2–6 
(2004).
107. Shinohara Y: Antiplatelet cilostazol is 
effective in the prevention of pneumonia 
in ischemic stroke patients in the chronic 
stage. Cerebrovasc. Dis. 22(1), 57–60 (2006).
108. Teramoto S, Yamamoto H, Yamaguchi Y 
et al.: ACE inhibitors prevent aspiration 
pneumonia in Asian, but not Caucasian, 
elderly patients with stroke. Eur. Respir. J. 
29(1), 218–219 (2007).
109. Arai T, Sekizawa K, Ohrui T et al.: 
ACE inhibitors and protection against 
pneumonia in elderly patients with 
stroke. Neurology 64(3), 573–574 (2005).
110. Harada J, Sekizawa K: Angiotensin-
converting enzyme inhibitors and 
pneumonia in elderly patients with 
intracerebral hemorrhage. J. Am. Geriatr. 
Soc. 54(1), 175–176 (2006).
111. Ohkubo T, Chapman N, Neal B et al.: 
Effects of an angiotensin-converting 
enzyme inhibitor-based regimen on 
pneumonia risk. Am. J. Respir. Crit.
Care Med. 169(9), 1041–1045 (2004).
112. Sekizawa K, Matsui T, Nakagawa T, 
Nakayama K, Sasaki H: ACE inhibitors and 
pneumonia. Lancet 352(9133), 1069 
(1998).
113. Nakagawa T, Wada H, Sekizawa K, 
Arai H, Sasaki H: Amantadine and 
pneumonia. Lancet 353(9159), 1157 
(1999).
114. Yrjanheikki J, Keinanen R, Pellikka M, 
Hokfelt T, Koistinaho J: Tetracyclines 
inhibit microglial activation and are 
neuroprotective in global brain ischemia. 
Proc. Natl Acad. Sci. USA 95(26), 
15769–15774 (1998).
115. Yrjanheikki J, Tikka T, Keinanen R et al.: 
A tetracycline derivative, minocycline, 
reduces inflammation and protects against 
focal cerebral ischemia with a wide 
therapeutic window. Proc. Natl Acad. Sci. 
USA 96(23), 13496–13500 (1999).
116. Zemke D, Majid A: The potential of 
minocycline for neuroprotection in human 
neurologic disease. Clin. Neuropharmacol. 
27(6), 293–298 (2004).
117. Rothstein JD, Patel S, Regan MR et al.: 
β-lactam antibiotics offer neuroprotection by 
increasing glutamate transporter expression. 
Nature 433(7021), 73–77 (2005).
118. Kwan, J, Englyst, N, Roberts, HC: Do we 
really understand the pathophysiology and 
clinical impact of post-stroke infection? 
Stroke 37, 1656 (2006). 
119. Nakajoh K, Nakagawa T, Sekizawa K et al.: 
Relation between incidence of pneumonia 
and protective reflexes in post-stroke 
patients with oral or tube feeding. J. Intern. 
Med. 247(1), 39–42 (2000).
120. Rowat AM, Wardlaw JM, Dennis MS, 
Warlow CP: Patient positioning influences 
oxygen saturation in the acute phase of 
stroke. Cerebrovasc. Dis. 12(1), 66–72 
(2001).
121. Stensballe J, Tvede M, Looms D et al.: 
Infection risk with nitrofurazone-
impregnated urinary catheters in trauma 
patients: a randomized trial. Ann. Intern. 
Med. 147(5), 285–293 (2007).
122. Niel-Weise BS, van den Broek PJ: Urinary 
catheter policies for short-term bladder 
drainage in adults. Cochrane Database 
Syst. Rev. (3), CD004203 (2005).